Navigation Links
Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy
Date:3/3/2010

tients who may benefit from a skin cancer treatment in development by GSK.

GSK's MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) candidate is currently being evaluated as an adjuvant treatment in melanoma biopsy specimens in the Phase III clinical study DERMA.  To be eligible to receive GSK's MAGE-A3 ASCI, patients must have MAGE-A3 expressing melanoma tumors.  

Under terms of the agreement, Abbott, in conjunction with GSK, will develop and commercialize a PCR (polymerase chain reaction) test for use on the Abbott m2000™ automated molecular instrument system.  The test will be designed to detect MAGE-A3, a tumor-specific antigen that is expressed in skin cancer and a wide variety of other cancers, but not in normal cells.  In July 2009, both companies announced a similar collaboration and Phase III investigation for the MAGE-A3 marker in non-small-cell lung cancer.

Currently, there are no nucleic acid-based tests approved by the U.S. Food and Drug Administration for use in identifying patients who may derive treatment benefits from targeted skin cancer therapies.  Abbott, in collaboration with GSK, will seek regulatory approval for the test in several markets, including the United States and Europe. '/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
(Date:8/28/2015)...  IP Shakti, LLC, today announced that it has changed ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... identity signifies our transformation into a company focused on patent ... patent claim validity." ... Shield™ platform, the Company commenced a corporate re-branding initiative in ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... OMER ) today announced that it has obtained ... California to a new series of antifibrinolytic agents. These optimized ... surgical and traumatic bleeding. "This is a ... for patients. With the withdrawal of Trasylol® from the market ...
... Jan. 5, 2011 Karyopharm Therapeutics Inc., a pioneer ... modulators, announces the recruitment of a highly experienced cancer ... Chief Executive Officer. Dr. Kauffman will join Sharon Shacham, ... and Development, as its executive management team. Kauffman,s appointment ...
Cached Medicine Technology:Omeros Licenses Novel Antifibrinolytic Agents 2Omeros Licenses Novel Antifibrinolytic Agents 3Omeros Licenses Novel Antifibrinolytic Agents 4Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer 2Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer 3
(Date:8/30/2015)... ... , ... Natural Rest contains a unique mixture of vitamins and herbs that ... help to improve mood disorders and anxiety. Like all other Creative Medical Health products, ... of regenerative medicine conducted by Dr. Amit Patel of the University of Utah, one ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional ... will lead the expansion of global cosmeceutical and skin care brands. Mr. ... spent the last 25 years working in operations, purchasing and management for some ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... medical devices for the treatment of prostate cancer, has announced the roll-out of ... at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently ...
(Date:8/29/2015)... (PRWEB) , ... August 30, 2015 , ... On September ... (EMCC), one of the 10 regionally accredited Maricopa Community Colleges , will ... network with college students pursuing employment information and opportunities. , The Expo has expanded ...
(Date:8/29/2015)... Ambler, PA (PRWEB) , ... August 29, 2015 , ... ... at the Mesothelioma Applied Research Foundation (Meso Foundation) will present an educational ... starts at 7:00 PM and lasts through 9:30 PM (doors open at 6:45pm) at ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2
... odds, study shows , , WEDNESDAY, Dec. 31 (HealthDay News) ... raised the chances of a successful transplant when compared ... report. , The study, published in the Jan. 1 ... , got generally favorable reviews from American transplant experts. ...
... counseling helps with connective tissue-related pain, , , WEDNESDAY, ... with aches and pains that refuse to go ... long-practiced but relatively obscure alternative therapy called naprapathy. ... hands-on manipulation, nutritional counseling and, sometimes, therapeutic "modalities," ...
... Percent Funding Cuts in 2009 Will Reduce Payments for Home ... , WASHINGTON, Dec. 31 As Americans nationwide prepare to ... to 2009 with great unease due to significant Medicare policy ... alike. On January 1, two new policies in the ...
... WEDNESDAY, Dec. 31 (HealthDay News) -- Be careful with the ... in the ER this holiday season with an eye injury ... is opened improperly, the cork can travel up to 50 ... an eye, according to the American Academy of Ophthalmology. , ...
... help dieters,stick to their New Year,s resolution of ... Plan-a-Meal software that is iPhone and BlackBerry,friendly. , ... customize their meal plans throughout the day using,their ... dieters can quickly,include restaurant and take-out meals, grocery-bought ...
... Health Insurance provider, The HealthCare Solution, today announced the company is ... Taking a new approach, the California health insurance provider has partnered ... baby boomers to reduce their risk of memory loss that often ... ...
Cached Medicine News:Health News:A Better Method of Kidney Storage 2Health News:A Better Method of Kidney Storage 3Health News:Naprapathy: A Hands-On Approach to Pain Management 2Health News:Naprapathy: A Hands-On Approach to Pain Management 3Health News:Massive Cuts to Medicare Home Oxygen Therapy Benefit Taking Effect January 1 Creating Acute Anxiety Among Beneficiary and Provider Communities 2Health News:Massive Cuts to Medicare Home Oxygen Therapy Benefit Taking Effect January 1 Creating Acute Anxiety Among Beneficiary and Provider Communities 3Health News:PersonalDiets Announces New Plan-A-Meal Tools to Help With New Year's Weight Loss Resolutions! 2Health News: Baby-Boomers Find Help Qualifying for California Health Insurance with UK Neurosurgeon, Sim Farar 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: